There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an iso lated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1, wherein the polypeptide binds to th
There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an iso lated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 108 M-1, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO. 2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier. Also disclosed are prognostic and diagnostic assays.
대표청구항▼
We claim: 1. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 19-28, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity bindi
We claim: 1. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 19-28, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 108 M-1, and wherein the polypeptide comprises: with respect to said fragments of SEQ ID NO: 14, at least one of the position 6 Pro and the position 73 Asp; with respect to said fragments of SEQ ID NO: 19, the position 2 Ser; with respect to said fragments of SEQ ID NO:20, the position 5 Pro; with respect to said fragments of SEQ ID NO:21, both the position 6 Leu and the position 73 Asp; with respect to said fragments of SEQ ID NO:22, the position 16 Gln; with respect to said fragments of SEQ ID NO:23, the position 18 Leu; with respect to said fragments of SEQ ID NO:24, the position 21 Asp, Ala or Val; with respect to said fragments of SEQ ID NO:25, the position 36 Ile; with respect to said fragments of SEQ ID NO:26, the position 54 Arg; with respect to said fragments of SEQ ID NO:27, the position 64 Leu; or with respect to said fragments of SEQ ID NO:28, both the position 6 Pro and the position 73 Asn. 2. The isolated polypeptide of claim 1, wherein the isolated polypeptide is from about 69 to 79 contiguous residues in length. 3. The isolated polypeptide of claim 1, wherein the isolated polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 14 and 19-28. 4. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 15, 29-38, and fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 108 M-1, and wherein the polypeptide comprises: with respect to said fragments of SEQ ID NO: 15, at least one of the position 346 Pro and the position 413 Asp; with respect to said fragments of SEQ ID NO:29, the position 342 Ser; with respect to said fragments of SEQ ID NO:30, the position 345 Pro; with respect to said fragments of SEQ ID NO:31, both the position 346 Leu and the position 413 Asp; with respect to said fragments of SEQ ID NO:32, the position 356 Gln; with respect to said fragments of SEQ ID NO:33, the position358 Leu; with respect to said fragments of SEQ ID NO:34, the position 361 Asp, Ala or Val; with respect to said fragments of SEQ ID NO:35, the position 376 Ile; with respect to said fragments of SEQ ID NO:36, the position 394 Arg; with respect to said fragments of SEQ ID NO:37, the position 404 Leu; or with respect to said fragments of SEQ ID NO:38, both the position 346 Pro and the position 413 Asn. 5. The isolated polypeptide of claim 4, wherein the isolated polypeptide is from about 350 to 419 contiguous residues in length and at least three N-linked glycosylation sites are present. 6. The isolated polypeptide of claim 4, wherein the isolated polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOS:15 and 29-38. 7. A pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of: (a) an isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 19-28, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 108 M-1, and wherein the polypeptide comprises: with respect to said fragments of SEQ ID NO: 14, at least one of the position 6 Pro and the position 73 Asp; with respect to said fragments of SEQ ID NO: 19, the position 2 Ser; with respect to said fragments of SEQ ID NO:20, the position 5 Pro; with respect to said fragments of SEQ ID NO:21, both the position 6 Leu and the position 73 Asp; with respect to said fragments of SEQ ID NO:22, the position 16 Gln; with respect to said fragments of SEQ ID NO:23, the position 18 Leu; with respect to said fragments of SEQ ID NO:24, the position 21 Asp, Ala or Val; with respect to said fragments of SEQ ID NO:25, the position 36 Ile; with respect to said fragments of SEQ ID NO:26, the position 54 Arg; with respect to said fragments of SEQ ID NO:27, the position 64 Leu; or with respect to said fragments of SEQ ID NO:28, both the position 6 Pro and the position 73 Asn; (b) an isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 15, 29-38, and fragments thereof of about 80 to 419 contiguous residues in length, wherein the C terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 108 M-1, and wherein the polypeptide comprises: with respect to said fragments of SEQ ID NO: 15, at least one of the position 346 Pro and the position 413 Asp; with respect to said fragments of SEQ ID NO:29, the position 342 Ser; with respect to said fragments of SEQ ID NO:30, the position 345 Pro; with respect to said fragments of SEQ ID NO:31, both the position 346 Leu and the position 413 Asp; with respect to said fragments of SEQ ID NO:32, the position 356 Gln; with respect to said fragments of SEQ ID NO:33, the position358 Leu; with respect to said fragments of SEQ ID NO:34, the position 361 Asp, Ala or Val; with respect to said fragments of SEQ ID NO:35, the position 376 Ile; with respect to said fragments of SEQ ID NO:36, the position 394 Arg; with respect to said fragments of SEQ ID NO:37, the position 404 Leu; or with respect to said fragments of SEQ ID NO:38, both the position 346 Pro and the position 413 Asn; (c) a monoclonal antibody that binds to the extracellular domain (ECD) of HER-2; and (d) combinations thereof, and a pharmaceutically acceptable carrier, with the proviso that where the composition comprises the monoclonal antibody it also comprises at least one of the agents of (a) or (b). 8. The pharmaceutical composition of claim 7, wherein the agent is the isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 19-28, and the fragments thereof. 9. The pharmaceutical composition of claim 7, wherein the agent is the combination of the isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 14, and 19-28, and the fragments thereof, and the monoclonal antibody that binds to the extracellular domain (ECD) of HER-2. 10. The pharmaceutical composition of claim 7, wherein the agent is the isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 15, 29-38, and the fragments thereof. 11. The pharmaceutical composition of claim 7, wherein the agent is the combination of the isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 15, 29-38, and the fragments thereof, and the monoclonal antibody that binds to the extracellular domain (ECD) of HER-2. 12. An isolated polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOS: 14 and 19-28, wherein the polypeptide comprises: with respect to SEQ ID NO: 14, at least one of the position 6 Pro and the position 73 Asp; with respect to SEQ ID NO: 19, the position 2 Ser; with respect to SEQ ID NO:20, the position 5 Pro; with respect to SEQ ID NO:21, both the position 6 Leu and the position 73 Asp; with respect to SEQ ID NO:22, the position 16 Gln; with respect to SEQ ID NO:23, the position18 Leu; with respect to SEQ ID NO:24, the position 21 Asp, Ala or Val; with respect to SEQ ID NO:25, the position 36 Ile; with respect to SEQ ID NO:26, the position 54 Arg; with respect to SEQ ID NO:27, the position 64 Leu; or with respect to SEQ ID NO:28, both the position 6 Pro and the position 73 Asn. 13. An isolated polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOS: 15 and 29-38, wherein the polypeptide comprises: with respect to SEQ ID NO: 15, at least one of the position 346 Pro and the position 413 Asp; with respect to SEQ ID NO:29, the position 342 Ser; with respect to SEQ ID NO:30, the position 345 Pro; with respect to SEQ ID NO:31, both the position 346 Leu and the position 413 Asp; with respect to SEQ ID NO:32, the position 356 Gln; with respect to SEQ ID NO:33, the position358 Leu; with respect to SEQ ID NO:34, the position 361 Asp, Ala or Val; with respect to SEQ ID NO:35, the position 376 Ile; with respect to SEQ ID NO:36, the position 394 Arg; with respect to SEQ ID NO:37, the position 404 Leu; or with respect to SEQ ID NO:38, both the position 346 Pro and the position 413 Asn. 14. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 14, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 108 M-1, and wherein with respect to said fragments, the polypeptide comprises at least one of the position 6 Pro and the position 73 Asp. 15. The isolated polypeptide of claim 14, wherein the isolated polypeptide is from about 69 to 79 contiguous residues in length. 16. The isolated polypeptide of claim 14, wherein the isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 14. 17. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 14. 18. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 15, and fragments thereof of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least 108 M-1, and wherein the polypeptide comprises at least one of the position 346 Pro and the position 413 Asp. 19. The isolated polypeptide of claim 18, wherein the isolated polypeptide is from about 350 to 419 contiguous residues in length and at least three N-linked glycosylation sites are present. 20. The isolated polypeptide of claim 18, wherein the isolated polypeptide comprises the amino acid sequence of SEQ ID NO:15. 21. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:15.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (58)
Plowman Gregory D. ; Culouscou Jean-Michel ; Shoyab Mohammed ; Siegall Clay B. ; Hellstrom Ingegerd ; Hellstrom Karl E., Antibodies to HER4, human receptor tyrosine kinase.
Cockerill George Stuart,GBX ; Carter Malcolm Clive,GBX ; Guntrip Stephen Barry,GBX ; Smith Kathryn Jane,GBX, Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-da (Oakland CA) Wang Alice M. (Walnut Creek CA), Cysteine-depleted muteins of biologically active proteins.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Carney Walter P. (North Andover MA) McKenzie Sara J. (Lynn MA), Detection and quantification of neu related proteins in the biological fluids of humans.
Suni Jukka (Helsinki FIX) Vaheri Antti (Helsinki FIX), Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Greene Mark I. (Penn Valley PA) Dobashi Kunio (Gunma PA JPX) Davis James G. (Philadelphia PA) Hamuro Junji (Yokahama JPX), Ligand for the neu gene product.
Lippman Marc E. (Bethesda MD) Lupu Ruth (Gaithersburg MD), Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses.
Waterfield Michael D. (London GB2) Schlessinger J. (Rehovot CA ILX) Ullrich Axel (South San Francisco CA), Method of detecting truncated epidermal growth factor receptors.
Baserga Renato ; Sell Christian ; Rubin Raphael, Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides.
Renato Baserga ; Christian Sell ; Raphael Rubin, Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides.
Singer,Elizabeth; Landgraf,Ralf; Slamon,Dennis J.; Eisenberg,David, Methods and materials for characterizing and modulating interaction between heregulin and HER3.
Hudziak Robert M. (Corvallis OR) Shepard H. Michael (Rancho Santa Fe CA) Ullrich Axel (Portola Valley CA) Fendly Brian M. (Half Moon Bay CA), Monoclonal antibodies directed to the HER2 receptor.
Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
Wels Winfried S. (Basel CHX) Hynes Nancy E. (Basel CHX) Harweth Ina-Maria (Grenzach-Wyhlen DEX) Groner Bernd (Basel CHX) Hardman Norman (Riehen CHX) Zwickl Markus (Basel CHX), Recombinant antibodies specific for a growth factor receptor.
Bennett, Brian D.; Goeddel, David V.; Lee, James M.; Matthews, William; Tsai, Siao Ping; Wood, William I., SAL-S1 receptor protein tyrosine kinase agonist antibodies.
Kluender Harold Clinton Eugene ; Benz Guenter Hans Heinz Herbert,DEX ; Brittelli David Ross ; Bullock William Harrison ; Combs Kerry Jeanne ; Dixon Brian Richard ; Schneider Stephan,DEX ; Wood Jill E, Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.